Explore every episode of the podcast Healthcare Logic for Growth
| Title | Pub. Date | Duration | |
|---|---|---|---|
| From Innovation to Revenue: How Healthcare Startups Turn a Great Product Into a Real Business | 15 Jun 2026 | 00:28:27 | |
Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:
Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider. Sources Referenced:
About Life Science Logic: Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier. Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| CMS Just Changed the Playbook for GLP-1...Consider the Following | 08 Jun 2026 | 00:28:05 | |
On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.
Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com. Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Pilot Era Is Over - AI in Healthcare Has Crossed Into Real ROI, and Small Companies Are Running Out of Time to Catch Up | 01 Jun 2026 | 00:40:53 | |
Healthcare is deploying AI tools at more than twice the rate of the broader economy — and for the first time at meaningful scale, the ROI is real and documented. In this episode, we unpack the NVIDIA State of AI in Healthcare 2026 survey and this week's Healthcare IT News report on AI payment alignment to answer the question every small healthcare company is quietly asking: what does the AI inflection point actually mean for my business right now? We cover three real-world scenarios across six audience segments — hospitals, home health agencies, digital health startups, pharma, biotech, and healthcare associations — and close with six specific actions you can take this week.
Links:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com. Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Medicaid Clock Is Already Ticking - What Every Small Healthcare Company Needs to Know Right Now | 25 May 2026 | 00:23:44 | |
On May 1st, 2026, Nebraska became the first state in the country to enforce Medicaid work requirements under the One Big Beautiful Bill Act - the sweeping federal law that includes nearly a trillion dollars in Medicaid cuts over ten years. Montana goes live July 1st. Iowa in December. And 43 states are federally required to follow by January 1st, 2027. In this episode, we break down what this means for small life science and healthcare companies, why the 2027 framing is the wrong planning frame, and five specific steps you should be taking right now to protect your revenue model and your commercial strategy. Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The FDA Just Changed the Rules on Coverage - What Early-Stage Companies Need to Know. | 18 May 2026 | 00:14:37 | |
On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math. In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.
Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at lifesciencelogic.com or reach me at Eric@lifesciencelogic.com. CONNECT
| |||
| Biotech in 2026: The Capital, Clinical, and Commercial Triple Threat | 11 May 2026 | 00:13:57 | |
Biotech in 2026 is operating inside a Triple Threat. In this episode, we break down the three forces hitting simultaneously: capital pressure that now demands commercial readiness alongside clinical proof, clinical complexity that has turned trial design into a commercial decision, and commercial infrastructure gaps that show up at the worst possible moment - right when you need them most.
If you're leading an early-stage biotech, preparing for a Series B, or building out your first commercial team, this episode gives you an honest picture of the landscape and three clear actions you can take right now. WHY THIS MATTERS The playbook that worked three years ago no longer applies. Capital is concentrating at later stages and investors are asking commercial questions earlier. Payers are demanding evidence that gets built into trial design - not bolted on after approval. And the gap between FDA approval and commercial success has not gotten any shorter.
What's different in 2026 is that these three pressures are compounding each other. A weak commercial story makes fundraising harder. A misaligned trial design creates payer problems at launch. And a company that hasn't built commercial infrastructure in parallel with clinical development finds itself scrambling when the window opens. This episode is about seeing all three threats clearly - and acting on them now. WHAT WE COVER
YOUR GO FORWARD STRATEGY — 3 ACTIONS FROM THIS EPISODE 1 - Map your trial endpoints against payer coverage criteria - do this before your next protocol amendment, not after approval 2 - Build your one-page commercial narrative before your next investor meeting - your clinical story needs a commercial chapter 3 - Book one payer conversation this quarter - not to pitch, but to listen and learn what they'll actually need to see CONNECT
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Honest State of Early-Stage Life Science in 2026: What Every Biotech, Pharma, MedTech, and Digital Health Company Is Really Up Against | 04 May 2026 | 00:17:02 | |
In this opening episode of the Early-Stage Life Science series, host Eric delivers an honest 30,000-foot assessment of what early-stage life science companies are up against in 2026. Not the headline version. The operational reality. WHY THIS EPISODE MATTERS The life sciences landscape looks strong from the outside - a recovering biotech index, active M&A, and AI transforming drug discovery at a real pace. But underneath those headlines, the environment for early-stage companies has quietly gotten harder. Capital is concentrating at later stages. The regulatory and reimbursement infrastructure hasn't gotten simpler. NIH funding pullbacks are creating upstream pressure that will shape the pipeline for years. The companies that succeed in this environment are the ones who see it clearly - not the ones running on optimism alone. This episode gives you that clear view - and a practical starting point for building commercial strategy that holds up under the pressure of 2026. WHAT WE COVER
GO FORWARD STRATEGY - 5 ACTIONS YOU CAN TAKE THIS WEEK 01 - Run a Commercial Readiness Check - Pull up your milestone map. Next to each clinical or regulatory milestone, write the commercial question it should be answering. If you can't write one, that's your gap. 02 - Map Capital Needs Against Commercial Milestones - Every dollar should be traceable to a milestone that strengthens your next raise. Line items that don't connect? That's your first efficiency opportunity. 03 - Have the Payer Conversation Earlier Than Feels Comfortable - If you haven't spoken with a payer medical director or pharmacy director about your product and evidence strategy, schedule that meeting this week. 04 - Audit Your Visibility in the Conversations That Matter - Identify the 3–5 conferences or forums where your key stakeholders gather. Is your company present and credible there? 05 - Name Your Biggest Commercial Blind Spot - Of the five challenge areas covered today, which one is your company most exposed to right now? Name it, write it down, and bring it to your next leadership meeting as a strategic priority.
CONNECT
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com © 2026 Life Science Logic. All rights reserved. | |||
| Welcome to 'Healthcare Logic for Growth.' | 01 May 2026 | 00:02:20 | |
Actionable Insights and Go-Forward-Strategies for Hospitals, Clinics, Home Health, and Emerging Healthcare Companies Welcome to Healthcare Logic for Growth, the podcast from Life Science Logic where clinical breakthroughs meet commercial reality, where hospitals near-term challenges are discussed and translate into keeping the doors open, where healthcare leadership and their team can discover a revenue architecture that drives and sustains growth. Hosted by Eric Marr, this show is for the builders - founders, executives, clinicians, and innovators across home health, clinics, pharma, biotech, medtech, digital health, health systems, and rural hospitals. Each week, we break down the logic behind real healthcare growth. Not just the science - but the strategy. We explore go-to-market plays, market intelligence, and practical frameworks for navigating healthcare’s unique complexity. From ideation to clinical application to commercialization and adoption, we share hard-earned lessons from both failures and wins. CONNECT
.
| |||